Mounjaro And Zepbound Shortages Targeted With $5.3 Billion Eli Lilly Investment

Memorial Day Weekend Forecast: ‘Severe’ Storms, Tornadoes, ‘Sweltering’ Heat And Cool Conditions—Here’s What To Expect In Your Region

Eli Lilly will invest an additional $5.3 billion into a new manufacturing site, boosting production for its weight loss and diabetes medications Mounjaro and Zepbound, the pharmaceutical firm said Friday, as demand for the popular drugs has resulted in shortages.

The investment will add 200 full-time jobs at the site, including positions for engineers, scientists, operating personnel and lab technicians, bringing the total workforce at the site to 900 full-time employees, according to Eli Lilly. Production at the site is expected to begin toward the end of 2026, Eli Lilly said, with escalated operations through 2028.We’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines. Text “Alerts” to 335-0739 or sign upThe $5.3 billion is the largest manufacturing investment in Eli Lilly’s 150-year history, chief executive David Ricks said in a statement.$18 billion.

Finance Finance Latest News, Finance Finance Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro. The drugmaker said Friday that it was more than doubling its investment in a site near its Indianapolis headquarters.
Source: AP - 🏆 728. / 51 Read more »